Home
About
Overview
Sharing Data
ORCID
Help
History (13)
Combined Pathologies in FTLD-TDP Types A and C.
Chow, Jarva
Natalizumab
Prescription Drug Diversion
PAK4 as a cancer immune-evasion target.
See All 13 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
PAK4 as a cancer immune-evasion target.
PAK4 as a cancer immune-evasion target. Nat Cancer. 2020 01; 1(1):18-19.
View in:
PubMed
subject areas
Humans
Neoplasms
p21-Activated Kinases
authors with profiles
Thomas Gajewski